Travere achieved record quarterly revenue of $220.2 million, driven by Filspari's expansion into FSGS, though management faces a CEO transition and increased competition in the IgA nephropathy market.
Travere Therapeutics reported Q3 2026 financial results, highlighted by $200.2 million in FILSPARI net product sales, representing 120% year-over-year growth. The company is advancing its Phase 3 HARMONY study of pegtibatinase with topline results expected in the second half of 2027 and plans to submit an IND for civorebrutinib by year-end.
“Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS.”
Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics
“As I prepare to transition leadership to Bradley Campbell in December, I have never been more confident in Travere’s future, supported by an exceptional team, an expanding pipeline and a shared commitment to delivering hope to patients.”
Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics
Travere Therapeutics CEO Eric M. Dube Sells $13.1M of Stock
Eric M. Dube, CEO, sold 243,735 shares of Travere Therapeutics, Inc. at $52.97 to $55.02 a share (average $53.82) in 3 transactions, worth $13.1M in total on Oct 15, 2026. Shares held after the trade: 432,886 (-15.3%).
Travere Therapeutics announced that Eric Dube, Ph.D., will step down as President, CEO, and Board member effective December 1, 2026. Bradley L. Campbell, former CEO of Amicus Therapeutics, has been appointed as his successor. Dr. Dube will remain as an Executive Advisor through February 15, 2027, to facilitate a smooth leadership transition.